GoodRx Holdings Analyst Price Targets - Benzinga

GoodRx Holdings Inc

GDRXNASDAQ

Trade with Public

Trade with Public

$3.45

-0.01-0.29%

al cierre: Sep 2, 5:00 PM EST

$3.44

-0.008-0.23%

After hour: 5:10 PM EST

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

GoodRx Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for GoodRx Holdings (GDRX).

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

7Buy

6Hold

2Sell

Consensus RatingOutperform# Analysts15Avg. Consensus PT$6Upside to Avg. PT+67.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 21, 2026	Barclays	Glen Santangelo	PT Raise	Underweight	$3→$4
Aug 13, 2026	UBS	Kevin Caliendo	PT Raise	Neutral	$3→$4
Aug 11, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$5
Aug 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$4→$5
Aug 7, 2026	Wells Fargo	Stan Berenshteyn	PT Raise	Overweight	$4→$5
May 14, 2026	Citigroup	Daniel Grosslight	PT Raise	Buy	$4→$4
May 11, 2026	TD Cowen	Charles Rhyee	PT Raise	Buy	$3→$4
Mar 4, 2026	Wells Fargo	Stan Berenshteyn	PT Cut	Overweight	$7→$4
Mar 3, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$4
Mar 2, 2026	Goldman Sachs	Eric Sheridan	PT Cut	Neutral	$4→$3
Feb 27, 2026	Mizuho	Steven Valiquette	PT Cut	Neutral	$4→$3
Feb 27, 2026	JP Morgan	Lisa Gill	Downgrade	Overweight→Neutral	—
Jan 22, 2026	Jefferies	Glen Santangelo	Downgrade	Buy→Hold	$5→$3
Jan 9, 2026	Citigroup	Daniel Grosslight	PT Cut	Buy	$5→$5
Dec 18, 2025	Morgan Stanley	Craig Hettenbach	PT Cut	Equal-Weight	$5→$4
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Underweight	$3
Nov 11, 2025	JP Morgan	Lisa Gill	PT Cut	Overweight	$6→$5
Nov 10, 2025	TD Cowen	Charles Rhyee	PT Cut	Buy	$7→$6
Nov 6, 2025	UBS	Kevin Caliendo	PT Cut	Neutral	$4→$4
Nov 6, 2025	Mizuho	Steven Valiquette	PT Cut	Neutral	$5→$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Underweight on GoodRx Holdings, Raises Price Target to $4

Barclays analyst Glen Santangelo maintains GoodRx Holdings (NASDAQ:GDRX) with a Underweight and raises the price target from $3 to $4.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ:GDRX) with a Neutral and raises the price target from $2.5 to $3.75.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $5

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $5

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $4 to $5.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on GoodRx Holdings, Raises Price Target to $4

Citigroup analyst Daniel Grosslight maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3.5 to $4.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on GoodRx Holdings, Raises Price Target to $4

TD Cowen analyst Charles Rhyee maintains GoodRx Holdings (NASDAQ:GDRX) with a Buy and raises the price target from $3 to $4.

Benzinga Newsdesk